Genus Oncology GO-203-2c gets FDA orphan drug status
The company’s lead drug candidate, GO-203-2c is currently being studied in a Phase I trial which aims to determine the safety and tolerability, and potential anti-tumor activity of
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.